Results 131 to 140 of about 21,799 (237)

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

Development of a High‐Throughput LC–MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring

Biomedical Chromatography, Volume 40, Issue 3, March 2026.
ABSTRACT Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM).
Yuan Yao, Guang‐Yao Huang, Ting‐Ting Wu, Ting‐Fei Tan, Feng‐Mei Hu, Chao Huang, Shan Gao, An‐Ping Guo, Jun‐Ping Wang   +8 more
wiley   +1 more source

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj  

IBD Care Organisation of the Future: Value for Money

JCC Plus, Volume 1, Issue 2, March 2026.
IBD care organisation of the future: value for money. The principles of value‐based healthcare offer a framework for future‐proof IBD care. This article highlights strategies based on these principles to improve patient outcomes, cost‐efficiency and sustainability of IBD care. ABSTRACT Healthcare systems worldwide are undergoing profound transformation
Stefan Delen, Gert Van Assche, Marc Ferrante   +2 more
wiley   +1 more source

Diagnostic and prognostic value of fecal, serum and endoscopic markers in inflammatory bowel disease and colorectal cancer [PDF]

, 2018
Background. The most important goals of the recent therapies of inflammatory bowel disease (IBD) are to induce and maintain clinical remission and mucosal healing (MH), which can be achieved with anti-TNF-α biological therapy.
Rutka Mariann
core  

Limited Options to Manage Specialty Drug Spending [PDF]

, 2012
Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core  

Loss of Response to Anti‐Tumor Necrosis Factor Alpha Therapy in Patients With Inflammatory Bowel Disease: A Real‐World Comparison of Combination Therapy Versus Monotherapy

JGH Open, Volume 10, Issue 3, March 2026.
ABSTRACT Objectives The success of anti‐TNFα agents has changed the landscape of treatment for inflammatory bowel diseases (IBD). One major limitation to this success is the secondary loss of response (sLOR) phenomenon. Combination therapy with immunomodulating agents has been shown to be effective in reducing the sLOR process.
Faris Chater, Maja Kopczynska, Mahdi Saeidinejad, Richard Gentry, Jack Smith, Catherine Stansfield, Arash Assadsangabi   +6 more
wiley   +1 more source

Review of medicine registration system in Tanzania [PDF]

, 2019
Philosophiae Doctor - PhDRegistration of medicines is an essential function of the national medicine regulatory system of any country. Since the start of the medicine registration system in Tanzania in early 2000s, no systematic review has been carried
KISOMA, SUNDAY
core  

Medicine Development and Access for Rare Diseases: Can We Do Better?

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Recent advances in molecular biology and genomics have significantly enhanced our understanding of rare diseases. While enabling the development of highly targeted therapies, it also leads to complexity in the development, regulation, and accessibility of orphan medicines.
Carla E. M. Hollak, Noa Rosenberg, Colinda Post, Nina Stolwijk, Evert Manders, Daphne Schoenmakers, Bart Penninx, Niels Reijnhout, Kathelijn Verdeyen, Roel Jonker, Annet M. Bosch, Mirjam Langeveld, Vincent van der Wel, Saco de Visser, Sibren van den Berg   +14 more
wiley   +1 more source

Out of the Straitjacket. [PDF]

, 2018
Weinstein, Michael
core   +2 more sources